Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study - PubMed
5 hours ago
- #Real-World Study
- #Cardiovascular Prevention
- #Tirzepatide
- Study evaluates early tirzepatide use after acute myocardial infarction (AMI) or ischemic stroke in non-diabetic patients.
- Retrospective analysis using TriNetX Research Network data from 110 healthcare organizations.
- Included adults ≥18 years with BMI ≥27 kg/m² without diabetes, experiencing AMI or ischemic stroke (June 2022 - November 2025).
- Propensity score matching (1:1) balanced 28 covariates, resulting in 833 patients per cohort.
- Tirzepatide use within 14 days of AMI/stroke linked to lower risks of all-cause ER visits/hospitalizations, acute kidney injury (AKI), ischemic stroke, and heart-failure hospitalization.
- No significant difference in major adverse cardiovascular events (MACE) risk.
- Findings suggest tirzepatide may benefit secondary cardiovascular prevention in non-diabetic patients.